The University of Tennessee Health Science Center and Regional One Health are partnering on a clinical trial program in Memphis to evaluate a drug for COVID-19 treatment. The Memphis medical college and hospital announced Thursday they will provide late-stage trials for Regeneron’s REGN-COV2, an antibody cocktail the company is investigating for possible treatment and prevention for COVID-19.
Also:
- September 24: Local Memphis
- September 24: Memphis Business Journal
- September 24: One News Page
- September 24: WMC-TV
- September 24: WMC Action News 5 at 4:00PM
- September 24: WMC Action News 5 at 5:00PM
- September 25: Daily Memphian
- September 25: Medical Health News
- September 25: WREG News Channel 3 Live at 9
- September 25: WMC-TV
- September 25: WMC Action News 5 at Noon
- September 25: WMC Action News 5 at 5:00PM
- September 25: WMC Action News 5 at 6:00PM
- September 26: WMC Action News AM at 5:00AM
- September 26: WMC Action News AM at 6AM
- September 26: WMC Action News 5 Today
- September 26: Region 8 News at Ten
- September 27: Trial Site News